As an asthma sufferer, you may find yourself with dual loyalties. On the one hand, you want to protect the environment for your own health and for the sake of future generations inhabiting this planet. On the other hand, you want to maintain good asthma control so that you can breathe. Although there shouldn't be any conflict between these two goals, you may have sensed that there has been ever since pharmaceutical manufacturers started eliminating asthma medications using chlorofluorocarbons (CFCs) to propel the mist from your inhalers. CFCs are harmful to the environment. Together with similar molecules formerly used in refrigeration and air conditioning, CFCs interact with gases high in the atmosphere above us, depleting ozone from the stratosphere. Enlarging ozone holes in the atmosphere and the role of CFCs in causing their formation were discovered by scientists in the 1980s, and by 1989 countries around the world agreed to stop manufacture and sale of most CFCs. Slowly we have seen elimination of CFCs as propellants for our metered-dose inhalers.
Since
then, other asthma medications have been released as metered-dose inhalers with
HFA propellants, including the steroids beclomethasone (formerly Beclovent and
Vanceril) as Qvar-HFA, fluticasone as Flovent-HFA, and newest among them,
ciclesonide, as Alvesco-HFA. However,
not all medications made the transition to the new propellant. The inhaled steroids, triamcinolone
(Azmacort) and flunisolide (Aerobid), simply disappeared from the market, as
did the once widely used anti-inflammatory medication, cromolyn (Intal). Other manufacturers released their asthma
medications not as metered-dose inhalers at all but in a dry-powder
formulation. The inhaled steroids
budesonide (Pulmicort), fluticasone (Flovent), and mometasone (Asmanex) are
available as multi-dose dry-powder inhalers.
This
summer marks the end of the road for CFC-driven inhalers. The last two are both quick-acting
bronchodilators -- albuterol plus ipratropium in the Combivent inhaler (more
often used to treat COPD than asthma) and pirbuterol in the Maxair
Autohaler. Maxair will simply be
withdrawn from the market; Combivent is being released using a novel delivery
system, called a "soft mist" inhaler (Combivent Respimat). This latter new system is a tribute to the inventiveness
of pharmaceutical manufacturers as they work to make inhaled medications
available in ways that are both effective and safe for our environment.
The
silver lining in all of this is that globally the amount of CFC-type chemicals
in the atmosphere decreased by approximately 10% between 1994 and 2008. It is predicted that the ozone hole over the
Antarctic will decrease in size by 2015 and may completely recover by
2050. We care about the protective ozone
layer in our planet's atmosphere because its depletion is associated with
increased exposure to ultraviolet light (UVB) on the planet's surface,
increasing our risk of skin cancers and cataracts and potentially causing damage to
crops and sea life. With the help of scientific
expertise, global cooperation, and some flexibility on our parts, it may be
possible to "have our cake and eat it too," or in this case, to protect
"spaceship earth" and breathe freely too.